LEXICON PHARMACEUTICALS, INC. Current Portion of Long-Term Debt
LEXICON PHARMACEUTICALS, INC. (LXRX) had Current Portion of Long-Term Debt of $0 as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LongTermDebtCurrent · last filed 2026-08-06
- 2026-06-30: Long-term Debt, Current Maturities $0.00.
- 2026-03-31: Long-term Debt, Current Maturities $0.00.
- 2025-12-31: Long-term Debt, Current Maturities $4.59M.
- 2025-03-31: Long-term Debt, Current Maturities $42.06M.
| Period end | Long-term Debt, Current Maturities | Long-term Debt, Current Maturities as first filed |
|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $4.59M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $42.06M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-05 | |
| 2021-12-31 | $0.00 10-K · filed 2022-03-10 | |
| 2021-09-30 | $11.69M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $11.68M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $11.66M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $11.65M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $8.69M 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $10.46M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $10.73M 10-Q · filed 2020-04-27 | |
| 2019-12-31 | $11.01M 10-K · filed 2021-03-12 | |
| 2019-09-30 | $11.29M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $1.11M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $1.11M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $1.11M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $1.11M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $12.90M 10-Q · filed 2018-07-30 | |
| 2018-03-31 | $13.52M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $14.09M 10-K · filed 2019-03-15 | |
| 2017-09-30 | $14.63M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $15.16M 10-Q · filed 2017-08-01 | |
| 2017-03-31 | $15.75M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $16.28M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $16.79M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $17.29M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $2.02M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $1.98M 10-K · filed 2017-03-06 | $2.02M 10-K · filed 2016-03-11 |
| 2015-09-30 | $18.79M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $19.25M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $19.71M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $20.17M 10-K · filed 2016-03-11 | |
| 2014-09-30 | $20.61M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $1.78M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $1.75M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $1.71M 10-K · filed 2015-03-12 | |
| 2013-09-30 | $1.68M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $22.68M 10-Q · filed 2013-08-01 | |
| 2013-03-31 | $1.61M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $1.57M 10-K · filed 2014-03-07 | |
| 2012-09-30 | $1.54M 10-Q · filed 2012-11-07 | |
| 2012-06-30 | $1.51M 10-Q · filed 2012-08-02 | |
| 2012-03-31 | $1.48M 10-Q · filed 2012-05-03 | |
| 2011-12-31 | $1.44M 10-K · filed 2013-03-11 | |
| 2011-09-30 | $1.41M 10-Q · filed 2011-11-01 | |
| 2011-06-30 | $1.38M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $1.14M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |